Literature DB >> 20527751

Pyrophosphate interactions at the transition states of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Yong Zhang1, Vern L Schramm.   

Abstract

Orotate phosphoribosyltransferases from Plasmodium falciparum and human sources (PfOPRT and HsOPRT) use orotidine as a slow substrate in the pyrophosphorolysis reaction. With orotidine, intrinsic kinetic isotope effects (KIEs) can be measured for pyrophosphorolysis, providing the first use of pyrophosphate (PPi) in solving an enzymatic transition state. Transition-state structures of PfOPRT and HsOPRT were solved through quantum chemical matching of computed and experimental intrinsic KIEs and can be compared to transition states solved with pyrophosphate analogues as slow substrates. PfOPRT and HsOPRT are characterized by late transition states with fully dissociated orotate, well-developed ribocations, and weakly bonded PPi nucleophiles. The leaving orotates are 2.8 A distant from the anomeric carbons at the transition states. Weak participation of the PPi nucleophiles gives C1'-O(PPi) bond distances of approximately 2.3 A. These transition states are characterized by C2'-endo ribosyl pucker, based on the beta-secondary [2'-(3)H] KIEs. The geometry at the 5'-region is similar for both enzymes, with C3'-C4'-C5'-O5' dihedral angles near -170 degrees . These novel phosphoribosyltransferase transition states are similar to but occur earlier in the reaction coordinate than those previously determined with orotidine 5'-monophosphate and phosphonoacetic acid as substrates. The similarity between the transition states with different substrate analogues supports similar transition state structures imposed by PfOPRT and HsOPRT even with distinct reactants. We propose that the transition state similarity with different nucleophiles is determined, in part, by the geometric constraints imposed by the catalytic sites.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20527751      PMCID: PMC2892240          DOI: 10.1021/ja102849w

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  45 in total

Review 1.  The depth of chemical time and the power of enzymes as catalysts.

Authors:  R Wolfenden; M J Snider
Journal:  Acc Chem Res       Date:  2001-12       Impact factor: 22.384

Review 2.  Inhibitors of de novo nucleotide biosynthesis as drugs.

Authors:  Richard I Christopherson; Stephen D Lyons; Paul K Wilson
Journal:  Acc Chem Res       Date:  2002-11       Impact factor: 22.384

Review 3.  Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases.

Authors:  M L Herrmann; R Schleyerbach; B J Kirschbaum
Journal:  Immunopharmacology       Date:  2000-05

Review 4.  Immunosuppressive drugs: the first 50 years and a glance forward.

Authors:  A C Allison
Journal:  Immunopharmacology       Date:  2000-05

Review 5.  Ordered biochemical program of gene expression in cancer cells.

Authors:  G Weber
Journal:  Biochemistry (Mosc)       Date:  2001-10       Impact factor: 2.487

Review 6.  Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development.

Authors:  Philippe J Guerin; Piero Olliaro; Francois Nosten; Pierre Druilhe; Ramanan Laxminarayan; Fred Binka; Wen L Kilama; Nathan Ford; Nicholas J White
Journal:  Lancet Infect Dis       Date:  2002-09       Impact factor: 25.071

7.  Purification, characterization and localization of mitochondrial dihydroorotate dehydrogenase in Plasmodium falciparum, human malaria parasite.

Authors:  J Krungkrai
Journal:  Biochim Biophys Acta       Date:  1995-04-13

8.  Transition state structure of Salmonella typhimurium orotate phosphoribosyltransferase.

Authors:  W Tao; C Grubmeyer; J S Blanchard
Journal:  Biochemistry       Date:  1996-01-09       Impact factor: 3.162

Review 9.  Thymidylate synthase inhibitors as anticancer agents: from bench to bedside.

Authors:  Edward Chu; Marc A Callender; Michael P Farrell; John C Schmitz
Journal:  Cancer Chemother Pharmacol       Date:  2003-06-18       Impact factor: 3.333

10.  Cytotoxic effects of inhibitors of de novo pyrimidine biosynthesis upon Plasmodium falciparum.

Authors:  K K Seymour; S D Lyons; L Phillips; K H Rieckmann; R I Christopherson
Journal:  Biochemistry       Date:  1994-05-03       Impact factor: 3.162

View more
  7 in total

1.  Uridine phosphorylase from Trypanosoma cruzi: kinetic and chemical mechanisms.

Authors:  Rafael G Silva; Vern L Schramm
Journal:  Biochemistry       Date:  2011-09-27       Impact factor: 3.162

Review 2.  Enzymatic transition states, transition-state analogs, dynamics, thermodynamics, and lifetimes.

Authors:  Vern L Schramm
Journal:  Annu Rev Biochem       Date:  2011       Impact factor: 23.643

3.  A humanized antibody inhibitor for cathepsin L.

Authors:  Xiaojing Shi; Yong Zhang
Journal:  Protein Sci       Date:  2020-08-07       Impact factor: 6.725

4.  Transition state analogues of Plasmodium falciparum and human orotate phosphoribosyltransferases.

Authors:  Yong Zhang; Gary B Evans; Keith Clinch; Douglas R Crump; Lawrence D Harris; Richard F G Fröhlich; Peter C Tyler; Keith Z Hazleton; María B Cassera; Vern L Schramm
Journal:  J Biol Chem       Date:  2013-10-24       Impact factor: 5.157

5.  Transition-state analysis of Trypanosoma cruzi uridine phosphorylase-catalyzed arsenolysis of uridine.

Authors:  Rafael G Silva; Mathew J Vetticatt; Emilio F Merino; Maria B Cassera; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2011-06-03       Impact factor: 15.419

6.  Leaving group activation and pyrophosphate ionic state at the catalytic site of Plasmodium falciparum orotate phosphoribosyltransferase.

Authors:  Yong Zhang; Hua Deng; Vern L Schramm
Journal:  J Am Chem Soc       Date:  2010-11-10       Impact factor: 15.419

7.  Ground-state destabilization in orotate phosphoribosyltransferases by binding isotope effects.

Authors:  Yong Zhang; Vern L Schramm
Journal:  Biochemistry       Date:  2011-05-06       Impact factor: 3.162

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.